非小细胞肺癌环氧化酶-2的增强表达及其临床意义

Overexpression of COX-2 and its clinical significance in non-small cell lung cancer

目的 探讨环氧化酶 2 (COX 2 )在非小细胞肺癌组织中的表达水平与其临床特征和预后的关系。 方法 收集外科切除的 79例非小细胞肺癌的组织标本石蜡切片 ,应用抗人COX 2抗体进行免疫组织化学染色 ,用COX 2阳性表达血管内皮细胞作阳性对照。 结果 肺腺癌和鳞癌COX 2阳性表达率分别为 85 % (2 8/ 33)和 5 7% (2 6 / 4 6 ) (P =0 0 13) ,COX 2的表达与腺癌的分化程度 (P =0 0 0 7)、肿瘤的大小 (P =0 0 11)和TNM分期有密切关系 (P =0 0 2 1) ,与鳞癌分化程度无明显关系 (P =0 5 5 0 )。COX 2阳性组患者 5年生存率 2 7 1% ,中位生存期 5 3个月 ;COX 2阴性组患者5年生存率 5 2 0 % ,中位生存期 6 1个月 ,2组差异有显著性意义 (P =0 0 2 9)。 结论 COX 2的增强表达与非小细胞肺癌的浸润性发展有密切关系 ,是非小细胞肺癌患者预后不良的风险因素之一。

ObjectiveTo study the relations among COX-2 expression in non-small cell lung cancer(NSCLC), its clinical characteristics and brognosis.MethodsImmunostaining was performed with COX-2 antibody to the surgically resected tissue samples from 79 patients with NSCLC. Vessel epithelium cell COX-2 expression was taken as positive control.ResultsThe positive rate of adenocarcinoma and squamous cell carcinoma was 85% and 57%, respectively( P =0.013). COX-2 expression was associated with the extent of adenocarcinoma differentiation, tumor size, and TNM period, but not with the extent of squamous cell carcinoma differentiation. In the COX-2 positive group, the 5-year survival rate and a median survival time were 27.1% and 53 months; however in the negative group they were 52.0% and 61 months ( P =0.029).ConclusionInvasive development of NSCLC is related to inceased expression of COX-2. COX-2 overexpression may be one of the risky factors for the prognosis of NSCLC.